An anti-prostate cancer benzofuran-conjugated iridium(III) complex as a dual inhibitor of STAT3 and NF-κB

Tian Shu Kang, Wanhe Wang, Hai Jing Zhong, Zhen Zhen Dong, Qi Huang, Simon Wing Fai Mok, Chung Hang Leung*, Vincent Kam Wai Wong, Edmond Dik Lung MA

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

48 Citations (Scopus)

Abstract

Four benzofuran-conjugated iridium(III) or rhodium (III)-based metal complexes are synthesized to screen as an inhibitor of STAT3 activity in prostate cancer cells. All complexes show the high stability and solubility in the biological system. In this study, an iridium(III) complex engages STAT3 and NF-κB to inhibit their translocation and transcriptional activities. Moreover, complex 1 shows more potential antiproliferative activity against DU145 cells and suppresses tumor growth in a prostate cancer xenograft mouse without observable adverse effects. Complex 1 may provide the basis for developing new therapeutic strategy in vivo and in vitro for the treatment of advanced prostate cancer.

Original languageEnglish
Pages (from-to)76-84
Number of pages9
JournalCancer Letters
Volume396
DOIs
Publication statusPublished - 28 Jun 2017

Scopus Subject Areas

  • Oncology
  • Cancer Research

User-Defined Keywords

  • Benzofuran-conjugated iridium(III) complex
  • Dual inhibitors
  • NF-κB
  • Prostate cells
  • STAT3

Fingerprint

Dive into the research topics of 'An anti-prostate cancer benzofuran-conjugated iridium(III) complex as a dual inhibitor of STAT3 and NF-κB'. Together they form a unique fingerprint.

Cite this